BTK Inhibitors in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Review key strategies for integrating BTK inhibition into management of your patients with B-cell malignancies with downloadable slides from a live expert-led meeting series.
Jeremy S. Abramson, MD, MMSc
Christopher R. Flowers, MD, MS

Downloadable Slideset

Download this slideset from our live meeting series to learn more about the optimal use of BTK inhibitors as therapy for patients with B-cell malignancies, including MCL, CLL/SLL, WM and MZL.

Jeremy S. Abramson, MD, MMSc Christopher R. Flowers, MD, MS Released: June 26, 2020
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue